aspen pharmacare hld - APNHY

APNHY

Close Chg Chg %
10.58 -0.11 -1.04%

Closed Market

10.47

-0.11 (1.04%)

Volume: 1.00K

Last Updated:

Nov 13, 2026, 3:21 PM EDT

Company Overview: aspen pharmacare hld - APNHY

APNHY Key Data

Open

$10.47

Day Range

10.47 - 10.47

52 Week Range

5.25 - 10.58

Market Cap

$4.45B

Shares Outstanding

428.25M

Public Float

N/A

Beta

1.10

Rev. Per Employee

N/A

P/E Ratio

268.94

EPS

N/A

Yield

79.09%

Dividend

$0.08

EX-DIVIDEND DATE

Oct 9, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

2.41K

 

APNHY Performance

1 Week
 
6.51%
 
1 Month
 
7.16%
 
3 Months
 
17.84%
 
1 Year
 
92.02%
 
5 Years
 
N/A
 

APNHY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About aspen pharmacare hld - APNHY

Aspen Pharmacare Holdings Ltd. manufactures and supplies branded and generic pharmaceutical products. It operates through the following segments: Commercial Pharmaceuticals, Injectables, and Manufacturing. The Commercial Pharmaceuticals segment consists of the following business sub segments: Sterile Focused Brands, which includes the Anaesthetics and Thrombosis portfolios; and Regional Brands, which are products that are managed on a regional basis. The Injectables segment focuses on injectable products which are primarily administered in hospitals and also prescribed and administered by physicians and in a retail pharmacy environment. The Manufacturing segment focuses on the following business sub segments: Active Pharmaceutical Ingredients, which involved in API Chemicals business and non-heparin biochemical API business; Heparin, which refers to the full value chain contribution from all heparin containing products; FDF Steriles, which includes all FDF sterile sales; and FDF Other, which consists of all non-sterile FDF products. The company was founded by Michael Guy Attridge in 1850 and is headquartered in Durban, South Africa.

APNHY At a Glance

Aspen Pharmacare Holdings Ltd.
Aspen Place, 9 Rydall Vale Park
Durban, KwaZulu-Natal 4019
Phone 27-31-580-8600 Revenue 2.06B
Industry Pharmaceuticals: Major Net Income 17.15M
Sector Health Technology Employees 7,625
Fiscal Year-end 06 / 2027
View SEC Filings

APNHY Valuation

P/E Current 268.938
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 247.979
Price to Sales Ratio 2.061
Price to Book Ratio 0.862
Price to Cash Flow Ratio 10.46
Enterprise Value to EBITDA 9.92
Enterprise Value to Sales 2.048
Total Debt to Enterprise Value 0.225

APNHY Efficiency

Revenue/Employee 270,510.751
Income Per Employee 2,249.731
Receivables Turnover 3.081
Total Asset Turnover 0.289

APNHY Liquidity

Current Ratio 2.544
Quick Ratio 1.682
Cash Ratio 0.986

APNHY Profitability

Gross Margin 39.323
Operating Margin 15.151
Pretax Margin -1.199
Net Margin 0.832
Return on Assets -0.737
Return on Equity -1.085
Return on Total Capital -0.897
Return on Invested Capital -0.873

APNHY Capital Structure

Total Debt to Total Equity 19.372
Total Debt to Total Capital 16.228
Total Debt to Total Assets 14.379
Long-Term Debt to Equity 11.817
Long-Term Debt to Total Capital 9.899
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Aspen Pharmacare Hld - APNHY

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
2.29B 2.39B 2.39B 2.06B
Sales Growth
-9.68% +4.26% -0.05% -13.61%
Cost of Goods Sold (COGS) incl D&A
1.27B 1.39B 1.38B 1.25B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
100.63M 105.43M 115.03M 113.40M
Depreciation
70.19M 74.27M 80.06M 81.69M
Amortization of Intangibles
30.45M 31.15M 34.97M 31.71M
COGS Growth
-8.34% +9.80% -0.68% -9.60%
Gross Income
1.02B 994.89M 1.00B 811.10M
Gross Income Growth
-11.31% -2.62% +0.84% -19.15%
Gross Profit Margin
+44.59% +41.65% +42.02% +39.32%
2023 2024 2025 2026 5-year trend
SG&A Expense
516.96M 528.25M 590.12M 498.60M
Research & Development
- - - -
-
Other SG&A
516.96M 528.25M 590.12M 498.60M
SGA Growth
-5.31% +2.18% +11.71% -15.51%
Other Operating Expense
- - - -
-
Unusual Expense
60.90M 121.03M 349.98M 267.43M
EBIT after Unusual Expense
443.79M 345.61M 63.10M 45.07M
Non Operating Income/Expense
(9.68M) 78.23M 24.23M 21.29M
Non-Operating Interest Income
29.77M 56.59M 19.71M 19.76M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
65.18M 118.52M 94.10M 91.09M
Interest Expense Growth
+55.70% +81.84% -20.60% -3.20%
Gross Interest Expense
67.31M 121.30M 106.66M 91.09M
Interest Capitalized
- 2.14M 2.78M 12.55M
Pretax Income
368.94M 305.32M (6.77M) (24.73M)
Pretax Income Growth
-30.98% -17.24% -102.22% -265.07%
Pretax Margin
+16.10% +12.78% -0.28% -1.20%
Income Tax
74.69M 70.00M 52.86M 27.80M
Income Tax - Current - Domestic
95.12M 99.87M 84.85M 66.07M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(20.43M) (29.87M) (31.99M) (38.27M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
294.25M 235.32M (59.63M) (52.53M)
Minority Interest Expense
- - - -
-
Net Income
294.25M 235.32M (59.63M) (52.53M)
Net Income Growth
-30.98% -20.03% -125.34% +11.92%
Net Margin Growth
+12.84% +9.85% -2.50% -2.55%
Extraordinaries & Discontinued Operations
- - - 69.68M
-
Discontinued Operations
- - - 69.68M
-
Net Income After Extraordinaries
294.25M 235.32M (59.63M) 17.15M
Preferred Dividends
- - - -
-
Net Income Available to Common
294.25M 235.32M (59.63M) 17.15M
EPS (Basic)
0.6624 0.5298 -0.1343 0.0386
EPS (Basic) Growth
-29.62% -20.02% -125.35% +128.74%
Basic Shares Outstanding
444.20M 444.20M 444.00M 444.10M
EPS (Diluted)
0.6624 0.5298 -0.1343 0.0386
EPS (Diluted) Growth
-29.62% -20.02% -125.35% +128.74%
Diluted Shares Outstanding
444.20M 444.20M 444.00M 444.10M
EBITDA
605.33M 572.07M 528.12M 425.90M
EBITDA Growth
-15.75% -5.49% -7.68% -19.36%
EBITDA Margin
+26.42% +23.95% +22.12% +20.65%

Aspen Pharmacare Hld in the News